170 related articles for article (PubMed ID: 29615987)
1. Mutacin 1140 Lantibiotic Variants Are Efficacious Against
Kers JA; Sharp RE; Defusco AW; Park JH; Xu J; Pulse ME; Weiss WJ; Handfield M
Front Microbiol; 2018; 9():415. PubMed ID: 29615987
[TBL] [Abstract][Full Text] [Related]
2. OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.
Kers JA; DeFusco AW; Park JH; Xu J; Pulse ME; Weiss WJ; Handfield M
PLoS One; 2018; 13(6):e0197467. PubMed ID: 29894469
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological, Toxicological, and Dose Range Assessment of OG716, a Novel Lantibiotic for the Treatment of
Pulse ME; Weiss WJ; Kers JA; DeFusco AW; Park JH; Handfield M
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670434
[TBL] [Abstract][Full Text] [Related]
4. Carboxyl Analogue of Mutacin 1140, a Scaffold for Lead Antibacterial Discovery.
Escano J; Ravichandran A; Salamat B; Smith L
Appl Environ Microbiol; 2017 Jul; 83(14):. PubMed ID: 28500042
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of the maximum tolerated dose and toxicokinetics of enteric-coated lantibiotic OG253 capsules.
Rajeshkumar NV; Kers JA; Moncrief S; Defusco AW; Park JH; Handfield M
Toxicol Appl Pharmacol; 2019 Jul; 374():32-40. PubMed ID: 31034929
[TBL] [Abstract][Full Text] [Related]
6. Blueprints for the rational design of therapeutic mutacin 1140 variants.
Kers JA; Sharp RE; Muley S; Mayo M; Colbeck J; Zhu Y; DeFusco AW; Park JH; Handfield M
Chem Biol Drug Des; 2018 Dec; 92(6):1940-1953. PubMed ID: 30010233
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of analogs of mutacin 1140 in systemic and cutaneous methicillin-resistant
Ju M; Joseph T; Hansanant N; Geng M; Williams M; Cothrell A; Buhrow AR; Austin F; Smith L
Front Microbiol; 2022; 13():1067410. PubMed ID: 36590413
[TBL] [Abstract][Full Text] [Related]
8. Site-directed mutations in the lanthipeptide mutacin 1140.
Chen S; Wilson-Stanford S; Cromwell W; Hillman JD; Guerrero A; Allen CA; Sorg JA; Smith L
Appl Environ Microbiol; 2013 Jul; 79(13):4015-23. PubMed ID: 23603688
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of pore formation and membrane disruption by the antimicrobial lantibiotic peptide Mutacin 1140.
Pokhrel R; Bhattarai N; Baral P; Gerstman BS; Park JH; Handfield M; Chapagain PP
Phys Chem Chem Phys; 2019 Jun; 21(23):12530-12539. PubMed ID: 31147666
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic activity of the lantibiotic MU1140.
Ghobrial OG; Derendorf H; Hillman JD
Int J Antimicrob Agents; 2009 Jan; 33(1):70-4. PubMed ID: 18835136
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
Nelson RL; Kelsey P; Leeman H; Meardon N; Patel H; Paul K; Rees R; Taylor B; Wood E; Malakun R
Cochrane Database Syst Rev; 2011 Sep; (9):CD004610. PubMed ID: 21901692
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
Nelson R
Cochrane Database Syst Rev; 2007 Jul; (3):CD004610. PubMed ID: 17636768
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
Bricker E; Garg R; Nelson R; Loza A; Novak T; Hansen J
Cochrane Database Syst Rev; 2005 Jan; (1):CD004610. PubMed ID: 15674956
[TBL] [Abstract][Full Text] [Related]
14. Modifying the Lantibiotic Mutacin 1140 for Increased Yield, Activity, and Stability.
Geng M; Smith L
Appl Environ Microbiol; 2018 Aug; 84(15):. PubMed ID: 29776930
[TBL] [Abstract][Full Text] [Related]
15. A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against
Thanissery R; Zeng D; Doyle RG; Theriot CM
Front Microbiol; 2018; 9():1206. PubMed ID: 29928268
[TBL] [Abstract][Full Text] [Related]
16. Current developments in lantibiotic discovery for treating Clostridium difficile infection.
Sandiford SK
Expert Opin Drug Discov; 2019 Jan; 14(1):71-79. PubMed ID: 30479173
[TBL] [Abstract][Full Text] [Related]
17. Efficacious Analogs of the Lantibiotic Mutacin 1140 against a Systemic Methicillin-Resistant Staphylococcus aureus Infection.
Geng M; Ravichandran A; Escano J; Smith L
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30275083
[TBL] [Abstract][Full Text] [Related]
18. [The history of the development and changes of quinolone antibacterial agents].
Takahashi H; Hayakawa I; Akimoto T
Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the novel artus C. difficile QS-RGQ, VanR QS-RGQ and MRSA/SA QS-RGQ assays for the laboratory diagnosis of Clostridium difficile infection (CDI), and for vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) screening.
Morris KA; Macfarlane-Smith LR; Wilcox MH
Eur J Clin Microbiol Infect Dis; 2017 May; 36(5):823-829. PubMed ID: 27987047
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.
Marchese A; Salerno A; Pesce A; Debbia EA; Schito GC
Chemotherapy; 2000; 46(4):253-66. PubMed ID: 10859431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
